Table 2.
| Trial |
Group types |
|
|---|---|---|
| Hall’s RCT | Control group |
Intervention group |
| Brief contact control | Staged care intervention | |
| Model inputs | ||
| Number of smokers | 159 | 163 |
| Mean age | 42 | 42 |
| Gender (male, %) | 29% | 32% |
| Quit rate at 18 mo | 19% | 25% |
| Mean total cost (18 mo) | £3748 | £4316 |
| SE of the mean cost | £440 | £392 |
| QALYs | – | – |
| SE of mean QALYs | – | – |
| Model outputs | ||
| Intervention BC | Intervention SCC | |
| Mean lifetime SAC | £4951 | £5523 |
| Mean lifetime QALY gains | 12.547 | 12.564 |
| Lifetime ICER | £33 744/QALY | |
| Probability be cost-effective at WTP threshold | ||
| £20 000 | 55% | 45% |
| £30 000 | 51% | 49% |
| Anthenelli’s RCT | Control group |
Intervention group |
|---|---|---|
| Placebo | Varenicline | |
| Model inputs | ||
| Number of smokers | 269 | 256 |
| Mean age | 47 | 45 |
| Gender (male, %) | 37% | 38% |
| Quit rate at 3 mo | 16% | 36% |
| Mean intervention cost (3 mo) | £0 | £164 |
| SE of the mean cost | £0 | £0 |
| QALYs | – | – |
| SE of mean QALYs | – | – |
| Model outputs | ||
| Placebo | Varenicline | |
| Mean lifetime SAC | £1446 | £1563 |
| Mean lifetime QALY gains | 9.817 | 9.856 |
| Lifetime ICER | £3002/QALY | |
| Probability be cost-effective at WTP threshold | ||
| £20 000 | 35% | 65% |
| £30 000 | 35% | 65% |
BC indicates brief contact; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; RCT, randomized controlled trial; SAC, smoking-attributable cost; SCC, staged care intervention; SE, standard error; WTP, willingness to pay.